Sarepta Therapeutics, Inc.
SRPTSarepta Therapeutics, Inc. is a medical research and drug development company with corporate offices and research facilities in Cambridge, Massachusetts, United States. Incorporated in 1980 as AntiVirals, shortly before going public the company changed its name from AntiVirals to AVI BioPharma soon with stock symbol AVII and in July 2012 changed name from AVI BioPharma to Sarepta Therapeutics and SRPT respectively. As of 2023, the company has four approved drugs.
Drugs in Pipeline
7
Phase 3 Programs
3
Upcoming Catalysts
1
Next Catalyst
Oct 31, 2026
34wMarket Overview
Stock performance and key metrics
1 upcoming, 0 past
SRP-9003
Limb-girdle Muscular Dystrophy
SRP-4045
Duchenne Muscular Dystrophy
Eteplirsen
Duchenne Muscular Dystrophy
RESTEN-MP
Coronary Artery Disease
AVI-4658 (Eteplirsen)
Duchenne Muscular Dystrophy (DMD)
AVI-4658 for Injection
Duchenne Muscular Dystrophy
SRP-4053
Duchenne Muscular Dystrophy
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
SRP-9003 | Phase 3 | Limb-girdle Muscular Dystrophy | - | - |
SRP-4045 | Phase 3 | Duchenne Muscular Dystrophy | - | - |
Eteplirsen | Phase 3 | Duchenne Muscular Dystrophy | - | - |
RESTEN-MP | Phase 2 | Coronary Artery Disease | - | - |
AVI-4658 (Eteplirsen) | Phase 2 | Duchenne Muscular Dystrophy (DMD) | - | - |
AVI-4658 for Injection | Phase 2 | Duchenne Muscular Dystrophy | - | - |
SRP-4053 | Phase 2 | Duchenne Muscular Dystrophy | - | - |
Duchenne Muscular Dystrophy
4 drugs in this indication
Coronary Artery Disease
1 drug in this indication
Limb-girdle Muscular Dystrophy
1 drug in this indication
Duchenne Muscular Dystrophy (DMD)
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)